Glioblastoma — frontier options in Colorado
19 open options
- TRIALPHASE2RECRUITING
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
ACT001 — 20 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Biopsy Procedure · Magnetic Resonance Imaging · Radiation Therapy — 127 sites
- TRIALPHASE3RECRUITING
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
SonoCloud-9 (SC9) · Carboplatin · Lomustine — 55 sites
- TRIALPHASE1RECRUITING
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-1255 Dose Escalation · RSC-1255 Dose Expansion — 3 sites
- TRIALPHASE2RECRUITING
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
PEP-CMV · Temozolomide · Tetanus Diphtheria Vaccine — 13 sites
- TRIALEARLY_PHASE1RECRUITING
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
Larotrectinib · Larotrectinib surgical — 21 sites
- TRIALPHASE1 / PHASE2RECRUITING
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Biospecimen Collection · Magnetic Resonance Imaging · Placebo Administration — 36 sites
- TRIALNANOT_YET_RECRUITING
Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being
Group Self-Management Sessions · Educational Materials Only — 2 sites
- TRIALPHASE2RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504 · Daraxonrasib · Nivolumab + Relatlimab FDC — 57 sites
- TRIALPHASE2RECRUITING
Study of Olutasidenib and Temozolomide in HGG
Olutasidenib + TMZ — 20 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Oral repotrectinib (TPX-0005) — 68 sites
- TRIALPHASE1 / PHASE2RECRUITING
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
LUTATHERA® (Lutetium Lu 177 dotatate) — 4 sites
- TRIALNARECRUITING
The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
Written Exposure-Based Coping Intervention (EASE) · Usual Care Control Condition — 2 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Temozolomide · Lomustine · Regorafenib — 63 sites
- EXPANDED ACCESSAVAILABLE
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
DCVax-L — 27 sites
- TRIALPHASE3RECRUITING
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
safusidenib · Placebo — 57 sites
- TRIALEARLY_PHASE1RECRUITING
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Lorlatinib · Lorlatinib with chemotherapy1 · Lorlatinib with chemotherapy 2 — 18 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
BAY 3713372 — 60 sites
- TRIALPHASE2RECRUITING
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Ribociclib · Everolimus · Temozolomide (TMZ) — 20 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.